Base de dados : MEDLINE
Pesquisa : C04.557.386.480 [Categoria DeCS]
Referências encontradas : 29816 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2982 ir para página                         

  1 / 29816 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29157619
[Au] Autor:Szalat R; Munshi NC
[Ad] Endereço:Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, M230 Boston, MA 02215, USA.
[Ti] Título:Diagnosis of Castleman Disease.
[So] Source:Hematol Oncol Clin North Am;32(1):53-64, 2018 02.
[Is] ISSN:1558-1977
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Castleman disease (CD) is a rare and heterogenous group of disorders sharing in common an abnormal lymph node pathology. CD comprises distinct subtypes with different prognoses. Unicentric CD and multicentric CD are featured by specific systemic manifestations and may be associated with Kaposi sarcoma, non-Hodgkin and Hodgkin lymphoma, and POEMS syndrome. Multicentric CD is classically associated with systemic symptoms and poorer prognosis. In this article, the authors review how to diagnose the disease, keeping in context the clinical findings, biochemical changes and complications associated with CD.
[Mh] Termos MeSH primário: Doença de Castleman/diagnóstico
Doença de Castleman/patologia
Linfonodos/patologia
[Mh] Termos MeSH secundário: Doença de Hodgkin/diagnóstico
Doença de Hodgkin/patologia
Seres Humanos
Linfoma não Hodgkin/diagnóstico
Linfoma não Hodgkin/patologia
Síndrome POEMS/diagnóstico
Síndrome POEMS/patologia
Sarcoma de Kaposi/diagnóstico
Sarcoma de Kaposi/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171122
[St] Status:MEDLINE


  2 / 29816 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27771623
[Au] Autor:Suri D; Bhattad S; Gupta A; Trehan A; Bansal D; Rajwanshi A; Das A; Rawat A; Singh S
[Ad] Endereço:Pediatric Allergy and Immunology Unit, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
[Ti] Título:Malignancies in Children with Human Immunodeficiency Virus Infection - Our Experience at Chandigarh, North India.
[So] Source:J Trop Pediatr;63(3):210-216, 2017 06 01.
[Is] ISSN:1465-3664
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background: With improved survival in children living with human immunodeficiency virus (HIV) infection (CLHIV), malignancies are being increasingly recognized. Patients and methods: Among the CLHIV registered at our institute from January 1994 to March 2015, children with malignancy were analysed in detail. Results: In total, 734 children affected by HIV were registered. Out of these, 11 children (9 boys, 2 girls) were diagnosed to have malignancy. Malignancy was the presenting feature of HIV infection in 4 children. High-grade non-Hodgkin lymphoma (NHL) was the most common malignancy noted in 9 of 11 (81%) children, whereas the remaining 2 children had Hodgkin's lymphoma. Survival in our cohort was 80% among children in whom chemotherapy was initiated, and overall survival was 36% (4 of 11 children). Conclusion: NHL was the most common malignancy in CLHIV in our cohort. Low-conditioning chemotherapy protocols along with initiation of anti-retroviral therapy resulted in improved outcomes in CLHIV with malignancy.
[Mh] Termos MeSH primário: Infecções por HIV/complicações
Neoplasias/complicações
[Mh] Termos MeSH secundário: Adolescente
Distribuição por Idade
Criança
Estudos de Coortes
Feminino
Infecções por HIV/diagnóstico
Infecções por HIV/epidemiologia
Seres Humanos
Índia
Linfoma Relacionado a AIDS/diagnóstico
Linfoma Relacionado a AIDS/epidemiologia
Linfoma Relacionado a AIDS/patologia
Linfoma não Hodgkin
Masculino
Registros Médicos
Neoplasias/mortalidade
Fatores de Risco
Distribuição por Sexo
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1093/tropej/fmw074


  3 / 29816 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465563
[Au] Autor:Marginean CO; Melit LE; Horvath E; Gozar H; Chincesan MI
[Ad] Endereço:Department of Pediatrics I.
[Ti] Título:Non-Hodgkin lymphoma, diagnostic, and prognostic particularities in children - a series of case reports and a review of the literature (CARE compliant).
[So] Source:Medicine (Baltimore);97(8):e9802, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Non-Hodgkin lymphoma remains an unpredictable condition in pediatric patients. PATIENT CONCERNS: Our first case describes an 8-year-old boy with a history of iron deficiency anemia, admitted in our clinic for recurrent abdominal pain, weight loss, loss of appetite, diarrheic stools, and fever. The second case also describes an 8-year-old boy admitted for abdominal pain and vomiting. The 3rd case refers to a 4 years and 10 months old boy admitted in our clinic with abdominal pain and loss of appetite, who was initially admitted in the Pediatrics Surgery Clinic with the suspicion of appendicitis. Our 4th patient was a 5-year-old boy admitted in our clinic for abdominal pain and intermittent diarrheic stools. DIAGNOSES: In the first case, the laboratory tests showed anemia, thrombocytosis, elevated inflammatory biomarkers, a low level of iron, and hypoproteinemia. The abdominal ultrasound and CT exam revealed an abdominal mass, and the histopathological exam established the diagnosis of diffuse large B-cell lymphoma of the bowel. In the second case, the laboratory tests pointed out anemia, elevated ESR and lactate dehydrogenase level, while both abdominal ultrasound and CT exams showed an abdominal mass. The histopathological exam confirmed the diagnosis of Burkitt lymphoma. Regarding our 3rd case, the laboratory findings revealed leukocytosis, anemia, thrombocytosis, increased inflammatory biomarkers, elevated LDH, and a low level of iron. The abdominal ultrasound and the CT scan revealed an abdominal mass which, according to the histopathological exam, was a Burkitt lymphoma. Due to the cranial CT findings the patient was diagnosed with IV stage Burkitt lymphoma with central nervous system metastases. In our 4th patients we found leukocytosis, anemia, mildly increased inflammatory biomarkers, a high level of LDH, hypoproteinemia, and a low level of serum Ir. Both ultrasound and abdominal CT exams were negative, but the exploratory laparotomy identified an abdominal mass, and according to the histopathological exam the patient was diagnosed with Burkitt lymphoma. INTERVENTIONS: All the patients followed chemotherapy (B-NHL BFM 04 protocol) and supportive treatment. OUTCOMES: The first patient died approximately 4 months after the completion of chemotherapy due to tumor relapse, the second patient died after the first cure of chemotherapy and the fourth patient died at approximately 2 years after the diagnosis. The third patient is recurrence-free after 2 years. LESSONS: Despite the advances in the management, NHL remains a fatal condition in pediatrics.
[Mh] Termos MeSH primário: Linfoma não Hodgkin/diagnóstico
[Mh] Termos MeSH secundário: Dor Abdominal/etiologia
Anemia Ferropriva/etiologia
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Asparaginase/uso terapêutico
Criança
Pré-Escolar
Daunorrubicina/uso terapêutico
Diarreia/etiologia
Evolução Fatal
Seres Humanos
Linfoma não Hodgkin/complicações
Linfoma não Hodgkin/tratamento farmacológico
Masculino
Prednisona/uso terapêutico
Prognóstico
Resultado do Tratamento
Vincristina/uso terapêutico
Vômito/etiologia
Perda de Peso
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
5J49Q6B70F (Vincristine); EC 3.5.1.1 (Asparaginase); VB0R961HZT (Prednisone); ZS7284E0ZP (Daunorubicin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009802


  4 / 29816 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29304125
[Au] Autor:Barisone GA; O'Donnell RT; Ma Y; Abuhay MW; Lundeberg K; Gowda S; Tuscano JM
[Ad] Endereço:Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis, Sacramento, California, United States of America.
[Ti] Título:A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activation.
[So] Source:PLoS One;13(1):e0190860, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Non-Hodgkin lymphoma (NHL) affects over 400,000 people in the United States; its incidence increases with age. Treatment options are numerous and expanding, yet efficacy is often limited by toxicity, particularly in the elderly. Nearly 70% patients eventually die of the disease. Many patients explore less toxic alternative therapeutics proposed to boost anti-tumor immunity, despite a paucity of rigorous scientific data. Here we evaluate the lymphomacidal and immunomodulatory activities of a protein fraction isolated from fermented wheat germ. Fermented wheat germ extract was produced by fermenting wheat germ with Saccharomyces cerevisiae. A protein fraction was tested for lymphomacidal activity in vitro using NHL cell lines and in vivo using mouse xenografts. Mechanisms of action were explored in vitro by evaluating apoptosis and cell cycle and in vivo by immunophenotyping and measurement of NK cell activity. Potent lymphomacidal activity was observed in a panel of NHL cell lines and mice bearing NHL xenografts. This activity was not dependent on wheat germ agglutinin or benzoquinones. Fermented wheat germ proteins induced apoptosis in NHL cells, and augmented immune effector mechanisms, as measured by NK cell killing activity, degranulation and production of IFNγ. Fermented wheat germ extract can be easily produced and is efficacious in a human lymphoma xenograft model. The protein fraction is quantifiable and more potent, shows direct pro-apoptotic properties, and enhances immune-mediated tumor eradication. The results presented herein support the novel concept that proteins in fermented wheat germ have direct pro-apoptotic activity on lymphoma cells and augment host immune effector mechanisms.
[Mh] Termos MeSH primário: Antineoplásicos/farmacologia
Células Matadoras Naturais/imunologia
Ativação Linfocitária/efeitos dos fármacos
Linfoma não Hodgkin/patologia
Extratos Vegetais/farmacologia
Triticum/metabolismo
[Mh] Termos MeSH secundário: Animais
Apoptose/efeitos dos fármacos
Linhagem Celular Tumoral
Feminino
Fermentação
Seres Humanos
Linfoma não Hodgkin/imunologia
Camundongos
Camundongos Nus
Proteínas de Plantas/farmacologia
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Plant Extracts); 0 (Plant Proteins)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180106
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190860


  5 / 29816 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29260599
[Au] Autor:Liewer S; Huddleston A
[Ad] Endereço:a Department of Pharmacy , Nebraska Medicine , Omaha , NE , USA.
[Ti] Título:Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors.
[So] Source:Expert Opin Investig Drugs;27(1):105-112, 2018 Jan.
[Is] ISSN:1744-7658
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Aurora kinases are essential mediators in cell mitosis. Amplification of these kinases can lead to the development of malignancy and may be associated with inferior survival. Alisertib is an oral aurora kinase inhibitor which has been shown to induce cell-cycle arrest and apoptosis in preclinical studies. It is currently under investigation for a wide variety of malignancies including hematologic (specifically Non-Hodgkin's lymphoma) and solid tumors. Areas covered: A PubMed search was performed to identify clinical studies reporting outcomes with alisertib. Promising results are notable in patients with peripheral T cell lymphoma in particular, forming the basis for the first phase 3 randomized trial of alisertib. Although it did show encouraging response rates, it failed to demonstrate superiority over the comparator arm at an interim analysis, halting further enrollment. Expert opinion: Despite disappointing early results, alisertib remains under investigation in a number of cancer types both as monotherapy and in combination with traditional cytotoxic chemotherapy, with encouraging results. Most common toxicities in early trials include myelosuppression alopecia, mucositis and fatigue. The relatively manageable toxicity profile of alisertib along with ease of dosing may allow it to be combined with other oral agents or traditional chemotherapy across a wide variety of malignancy types.
[Mh] Termos MeSH primário: Azepinas/administração & dosagem
Linfoma não Hodgkin/tratamento farmacológico
Neoplasias/tratamento farmacológico
Pirimidinas/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/administração & dosagem
Antineoplásicos/efeitos adversos
Antineoplásicos/farmacocinética
Apoptose/efeitos dos fármacos
Aurora Quinase A/antagonistas & inibidores
Azepinas/efeitos adversos
Azepinas/farmacocinética
Seres Humanos
Linfoma não Hodgkin/patologia
Neoplasias/patologia
Inibidores de Proteínas Quinases/administração & dosagem
Inibidores de Proteínas Quinases/efeitos adversos
Inibidores de Proteínas Quinases/farmacocinética
Pirimidinas/efeitos adversos
Pirimidinas/farmacocinética
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Azepines); 0 (MLN 8237); 0 (Protein Kinase Inhibitors); 0 (Pyrimidines); EC 2.7.11.1 (Aurora Kinase A)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171221
[St] Status:MEDLINE
[do] DOI:10.1080/13543784.2018.1417382


  6 / 29816 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29228840
[Au] Autor:Chang A; Schlafer D; Flowers CR; Allen PB
[Ad] Endereço:a Department of Hematology and Medical Oncology , Winship Cancer Institute, Emory University School of Medicine , Atlanta , GA , USA.
[Ti] Título:Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.
[So] Source:Expert Opin Investig Drugs;27(1):55-70, 2018 Jan.
[Is] ISSN:1744-7658
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Inhibitors against the PD-1/PD-L1 pathway are revolutionizing the treatment and management of malignancies. Areas covered: We summarize our current understanding of the function of PD-1, its role in immune evasion, the clinical data available that support the use of PD-1 antagonist in Hodgkin and non-Hodgkin lymphomas, and potential predictors of response. Expert opinion: We anticipate that in the next 10 years, agents that modulate the immune system such as PD-1 antagonists will be increasingly used in favor over traditional cytotoxic chemotherapeutic agents. PD-1 antagonists will be combined with future immunotherapies or used as adjuncts to cellular therapy to boost tumor-specific immune responses.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Doença de Hodgkin/tratamento farmacológico
Linfoma não Hodgkin/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/farmacologia
Biomarcadores Tumorais/metabolismo
Desenho de Drogas
Drogas em Investigação/farmacologia
Drogas em Investigação/uso terapêutico
Doença de Hodgkin/imunologia
Doença de Hodgkin/patologia
Seres Humanos
Linfoma não Hodgkin/imunologia
Linfoma não Hodgkin/patologia
Receptor de Morte Celular Programada 1/antagonistas & inibidores
Receptor de Morte Celular Programada 1/imunologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Biomarkers, Tumor); 0 (Drugs, Investigational); 0 (PDCD1 protein, human); 0 (Programmed Cell Death 1 Receptor)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE
[do] DOI:10.1080/13543784.2018.1416091


  7 / 29816 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29248129
[Au] Autor:Bas Y; Hassan HA; Adigüzel C; Bulur O; Ibrahim IA; Soydan S
[Ad] Endereço:Department of Pathology, Somalia-Turkey Education and Research Hospital, Mogadishu, Somalia; Hitit University Medical School, Çorum, Turkey. Electronic address: yilbas@yahoo.com.
[Ti] Título:The distribution of cancer cases in Somalia.
[So] Source:Semin Oncol;44(3):178-186, 2017 06.
[Is] ISSN:1532-8708
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The aim of this study was to investigate the frequency and distribution of cancer cases in a defined time period in Somalia. MATERIALS AND METHODS: A total of 403 cancer cases were diagnosed between January 01, 2016 and March 01, 2017 in the Department of Pathology at the Somalia Mogadishu-Turkey Education and Research Hospital or the Department of Oncology at Uniso Hospital, Somalia University. Data on cancer type, patient age, and gender were obtained from pathology reports and hospital records. RESULTS: Female patients totaled 49.6% (n = 200) and 50.4% of patients were male (n = 203). The youngest patient was 18 years of age, the oldest was 97, and the average age was 53.4 years. The 10 most common types of cancer were esophageal (n = 130, 32.3%), non-Hodgkin lymphoma (n = 35, 8.7%), liver (n = 26, 6.5%), breast (n = 24, 6.0%), skin (n = 17, 4.2%), thyroid (n = 13, 3.2%), brain (n = 12, 3.0%), bone (n = 11, 2.7%), colorectal (n = 11, 2.7%), and soft tissue (n = 11, 2.7%). The most common site of cancer in both males and females was the esophagus. CONCLUSION: These results show a high incidence of esophageal cancer in Somalia, and strongly suggest that environmental risk factors and nutritional habits have a strong impact in this population. Serious and extensive research on the etiology of esophageal cancer is required.
[Mh] Termos MeSH primário: Neoplasias/epidemiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Distribuição por Idade
Idoso
Idoso de 80 Anos ou mais
Neoplasias Ósseas/epidemiologia
Neoplasias Encefálicas/epidemiologia
Neoplasias da Mama/epidemiologia
Neoplasias Colorretais/epidemiologia
Neoplasias Esofágicas/epidemiologia
Feminino
Seres Humanos
Incidência
Neoplasias Hepáticas/epidemiologia
Linfoma não Hodgkin/epidemiologia
Masculino
Meia-Idade
Fatores de Risco
Distribuição por Sexo
Neoplasias Cutâneas/epidemiologia
Neoplasias de Tecidos Moles/epidemiologia
Somália/epidemiologia
Neoplasias da Glândula Tireoide/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171218
[St] Status:MEDLINE


  8 / 29816 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28455406
[Au] Autor:Petersen KB; Kjaergaard T
[Ad] Endereço:Department of ENT, Aarhus University Hospital, Aarhus C, Denmark.
[Ti] Título:Role of narrow band imaging in the diagnostics of sinonasal pathology.
[So] Source:BMJ Case Rep;2017, 2017 Apr 28.
[Is] ISSN:1757-790X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Malignancies of the nasal cavity and paranasal sinuses are well known, but have uncommon presentations. Late diagnosis and local extension are significant prognostic factors associated with a poorer treatment outcome. Thus, refinements of the diagnostic procedures to enhance the sensitivity of the clinical evaluation are desirable. We here describe a case of endonasal lymphoma, in which the lesion was hardly visible and initially ignored at ordinary white light (WLI) nasoendoscopy, but easily recognisable, clearly pathogenic and well demarcated when illuminated with narrow band imaging (NBI) at a later session. In general, with regard to mucosal-derived pathology of the upper aerodigestive tract, the diagnostic gain of NBI-assisted endoscopy in comparison with that of WLI has been proved in several articles. The focus has however been on neoplasm in laryngopharynx and oesophagus. The authors recommend broadening the use of NBI to include all evaluations of nasal mucosa, when malignancy is suspected.
[Mh] Termos MeSH primário: Linfonodos/diagnóstico por imagem
Linfoma não Hodgkin/patologia
Membrana Mucosa/patologia
Imagem de Banda Estreita/métodos
Cavidade Nasal/diagnóstico por imagem
Invasividade Neoplásica/diagnóstico por imagem
[Mh] Termos MeSH secundário: Idoso
Diagnóstico Diferencial
Endoscopia/métodos
Fluordesoxiglucose F18/metabolismo
Seres Humanos
Luz
Linfonodos/patologia
Linfoma não Hodgkin/complicações
Masculino
Mediastino/diagnóstico por imagem
Mediastino/patologia
Cavidade Nasal/patologia
Pescoço/diagnóstico por imagem
Pescoço/patologia
Invasividade Neoplásica/patologia
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons/métodos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0Z5B2CJX4D (Fluorodeoxyglucose F18)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  9 / 29816 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29188315
[Au] Autor:Wang C; Xia B; Ning Q; Zhao H; Yang H; Zhao Z; Wang X; Wang Y; Yu Y; Zhang Y
[Ad] Endereço:Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
[Ti] Título:High prevalence of hepatitis B virus infection in patients with aggressive B cell non-Hodgkin's lymphoma in China.
[So] Source:Ann Hematol;97(3):453-457, 2018 Mar.
[Is] ISSN:1432-0584
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:We retrospectively analyzed a large study to investigate the association of hepatitis B virus (HBV) with aggressive B cell non-Hodgkin's lymphoma (aggressive B-NHL) in China, where HBV is endemic. HBV was present in 39 aggressive B-NHL patients (10.46%), 13 indolent B-NHL patients (5.09%), 12 multiple myeloma (MM) patients (3.67%), and 5 solitary plasmacytoma (SP) patients (6.67%). HBV infection was significantly associated with increased risks for aggressive B-NHL (P < 0.01). HBV seems to have a very important role in the pathogenesis of aggressive B-NHL in China.
[Mh] Termos MeSH primário: Hepatite B/epidemiologia
Linfoma de Células B/epidemiologia
Linfoma não Hodgkin/epidemiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Criança
Pré-Escolar
China/epidemiologia
Feminino
Hepatite B/complicações
Seres Humanos
Linfoma não Hodgkin/complicações
Masculino
Meia-Idade
Invasividade Neoplásica
Prevalência
Estudos Retrospectivos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE
[do] DOI:10.1007/s00277-017-3188-2


  10 / 29816 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29419687
[Au] Autor:Popivanov GI; Bochev P; Hristoskova R; Mutafchiyski VM; Tabakov M; Philipov A; Cirocchi R
[Ad] Endereço:Clinic of Endoscopic, Endocrine surgery and Coloproctology.
[Ti] Título:Synchronous papillary thyroid cancer and non-Hodgkin lymphoma: Case report.
[So] Source:Medicine (Baltimore);97(6):e9831, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Differentiated thyroid cancer is the most common endocrine malignancy with concomitant hematological malignancy in 7%. PATIENT CONCERNS: We present a case of a synchronous papillary thyroid cancer and a follicular variant of non-Hodgkin lymphoma and discuss the possible diagnostic and treatment dilemmas. DIAGNOSIS: A 48-year-old female was reffered to our hospital with diagnosis "thyroid cancer". Due to a history compatable of synchronous lymphoproliferative disease we performed a computed tomography, which revealed multiple enlarged lymph nodes in the neck, mediastinum, axilla and abdomen. INTERVENTIONS: A total thyroidectomy with dissection of the central compartment was performed. The microscopic examination of thyroid gland revealed multifocal papilary thyroid cancer and metastaes from the same cancer plus aggressive follicular B-cell non-Hodgkin lymphoma in the lymph nodes. Despite the classic approach "solid cancer first", due to the advanced stage of lymphoma we first started the chemotherapy of NHL. She received 8 cycles of CHOP and I therapy with 129 mCi. Because of incomplete response 4 cycles Mabthera plus Bendamustin were added. The follow-up PET scan revealed complete remission of lymphoma and bilaterally enlarged single cervical lymph nodes, previously known to be iodine positive on I-SPECT/CT. She was sheduled for bilateral radical neck LND. OUTCOMES: Complete remission of NHL and residual single metastatic cervical lymph nodes requiring bilateral radical neck LND. LESSONS: The synchronous DTC and NHL is rare. To date, there is no standardized approach due to lack of experience. We suggest lymphoma first approach with synchronized and tailored multidisciplinary efforts. The molecular mechanisms of this link are poorly understood and yet remain to be elucidated.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Carcinoma Papilar
Linfoma não Hodgkin
Neoplasias da Glândula Tireoide
Tireoidectomia/métodos
[Mh] Termos MeSH secundário: Carcinoma Papilar/patologia
Carcinoma Papilar/cirurgia
Tomada de Decisão Clínica
Ciclofosfamida/administração & dosagem
Doxorrubicina/administração & dosagem
Monitoramento de Medicamentos/métodos
Feminino
Seres Humanos
Linfoma não Hodgkin/patologia
Linfoma não Hodgkin/terapia
Meia-Idade
Metástase Neoplásica
Estadiamento de Neoplasias
Neoplasias Primárias Múltiplas
Tomografia por Emissão de Pósitrons/métodos
Prednisona/administração & dosagem
Tomografia Computadorizada com Tomografia Computadorizada de Emissão de Fóton Único/métodos
Neoplasias da Glândula Tireoide/patologia
Neoplasias da Glândula Tireoide/cirurgia
Resultado do Tratamento
Vincristina/administração & dosagem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
5J49Q6B70F (Vincristine); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180209
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009831



página 1 de 2982 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde